Therapeutics for the treatment of glaucoma
US11505572B2 · kind B2 · utility
1Cited by
18References
37Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 22, 2020 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Oct 22, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65586
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.